A Phase 3 interventional study of Flucloxacillin Only Product in Oral Dose Form and Placebo Only Product in Oral Dose Form in Cellulitis of Leg, sponsored by University of Southampton. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by University of Southampton · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 258 studies in Pain with a site in United Kingdom — 18 open to participants now, 19 under way, 1 of them phase 3. Pain · United Kingdom.
Among the 258 studies in Pain with a site in United Kingdom, this one is the 31st largest by planned enrollment of the 214 interventional ones that give a count, is one of 15 that started in 2023, is one of 60 in phase 3, reaches primary completion later than 8 of the 18 other live ones, and was the 217th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →18 of the 258 studies in Pain with a site in United Kingdom are open now. Recruiting first, the newest first:
East and North Hertfordshire NHS Trust · Sites in United Kingdom
Ages 18+
East and North Hertfordshire NHS Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
University of Edinburgh · Sites in United Kingdom
Ages 16+ · Women only
University of Edinburgh · Sites in United Kingdom
Ages 18+
VM Therapeutics LLC · Sites in United Kingdom
Ages 18–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
258 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 36 · Phase 3 63 · Phase 4 19
First in 2001; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 334 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 78 across the 214 interventional studies, 127 across the 44 observational. Of the 207 that completed or were terminated, 61 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
125 of 258 have an industry lead sponsor. The 10 most frequent:
University of Southampton is the lead sponsor of 123 studies on the registry; 18 are open to participants now.
University of Southampton has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
7 of the studies in Pain with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07603960University of EdinburghWhole-Body Cryotherapy as a Non-Pharmacological Treatment to Reduce Chronic Pelvic Pain and Improve Quality of Life in People With Endometriosis | 2026-11 |
| NCT07466446University of EdinburghPost Intensive Care Accelerometery to Study and Support Recovery Outcomes | 2027-02-01 |
| NCT07597343Loughborough UniversityEnhancing Exercise Adherence Among Patients With Lateral Hip Pain | 2027-03-31 |
| NCT07072468VM Therapeutics LLCAnalgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) | 2027-06-30 |
| NCT07919080East and North Hertfordshire NHS TrustErgonomic Evaluation of Microscopic Ear Surgery With Exoskeleton: A Single Site Non-blinded Study | 2027-09 |
Add all 7 to your calendar (.ics) → With an account.
Among the 258 studies in Pain with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine whether a short course of oral flucloxacillin (5 days) is non-inferior to a standard course (7 days) in terms of pain over days 6-14 (indicative of persistence or recurrence associated with the symptoms of most importance to patients) in adults with cellulitis of the leg presenting in primary care.
Cellulitis is a deep infection of the skin and subcutaneous tissues and most often occurs in the legs. It is a painful condition that is associated with inflammation and swelling of the site, and often systemic symptoms such as fever, headache, muscle aches, malaise, and fatigue. Patients report feeling unwell and that it has a significant impact on their mobility and ability to carry out their usual activities. NICE guidelines recommend oral flucloxacillin 500-1000 mg four times daily for 5-7 days as first-line treatment for most patients with cellulitis in the community, but most prescriptions are dispensed for a 7-day course. We will be assessing the effectiveness and safety of a 5-day treatment vs. the standard 7-day treatment. We also aim to evaluate the cost-consequences of a shorter course from an NHS and personal perspective. Participants will be randomly allocated to one of two groups. In addition to usual care, participants will either be assigned to a 5-day oral flucloxacillin course or a standard 7-day flucloxacillin course. Participants will be prescribed a 5-day course of oral flucloxacillin, and two additional tablets will be posted to the participants which will either be the antibiotic or a placebo tablet. Participants will be asked to fill out daily questionnaires and express their experiences with the shortened course and taking part in the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Flucloxacillin 500mg four times a day (QDS) for 5 days (unblinded NHS prescription) followed by blinded placebo QDS for 2 days (5 days of antibiotic)
Drug: Flucloxacillin Only Product in Oral Dose Form · Drug: Placebo Only Product in Oral Dose Form
Flucloxacillin 500mg QDS for 5 days (unblinded NHS prescription) followed by flucloxacillin 500mg QDS (blinded) for 2 days (7 days of antibiotic)
Drug: Flucloxacillin Only Product in Oral Dose Form
Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment
Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
Pain assessment
Self-reported pain (measured using the Pain Numeric Rating Scale (0-10))
Time frame: Days 7-16
Use of additional antibiotics
Any reported use of antibiotics other than the initial 5 days of flucloxacillin and 2 days of IMP)
Time frame: Up to day 28
Patient-reported assessment of how well they are feeling
Numeric rating scale NRS (0-10) and assessed as repeated measures
Time frame: Days 6-14
Health related quality of life
EQ-5D-5L - values, and individual dimension (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) level scores using repeated measures.
Time frame: Days 6-14
Health related quality of life used to estimate Quality Adjusted- Life Years (QALYs)
EQ-5D-5L - values, and individual dimension (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) level scores using repeated measures.
Time frame: Days 6-14
Leg swelling and warmth
Participant reported questionnaire
Time frame: Day 7, 14, 21, 28
Time until self-reported recovery
Participant reported questionnaire
Time frame: Day 7, 14, 21, 28
Time until self-assessed extent of cellulitis starts to reduce (with no subsequent increase)
Participant reported questionnaire
Time frame: Day 7, 14, 21, 28
Hospital admissions
Number of hosptial admissions since randomisation, collected from primary care notes review
Time frame: 12 months
Recurrent cellulitis episodes over 12 months (number of episodes)
Recurrent cellulitis episodes over 12 months (number of episodes) since randomisation, collected from primary care notes review
Time frame: 12 months
Complications over 12 months
Number of reported complications since randomisation, collected from primary care notes review
Time frame: 12 months
Plan to share: No — Data from all centers will be analyzed together and published as soon as possible. Planned publication of the results in a high-impact peer-reviewed journal. Planned publication of protocol in a peer-review journal. The datasets generated and/or analyzed during the current study will be published as a supplement to the publication of the results. Individual investigators may not publish data concerning their patients that are directly relevant to questions posed by the trial until the Trial Management Group (TMG) has published its report. The TMG will form the basis of the Writing Committee and advise on the nature of publications.
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for May 2026, 33 months after the start.
Of 111 non-industry phase 3 interventional studies under Pain, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 33 months is close to that.
Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.